SAN DIEGO--(BUSINESS WIRE)--Renew Biopharma (“Renew”) announced today that Algae-C Inc. (“Algae-C”) has licensed rights to employ Renew’s proprietary engineered enzymes for use toward biosynthesis of cannabinoids in microalgae.
Renew Biopharma Appoints Experienced Pharmaceutical Executive, Dr. Steve Orndorff as Chief Operating Officer
SAN DIEGO--(BUSINESS WIRE)--Renew Biopharma, a leader in drug discovery and development of novel cannabinoids for human therapeutics, announced the addition of Steve Orndorff, Ph.D., as Chief Operating Officer.
SAN DIEGO--(BUSINESS WIRE)--Renew Biopharma today announced that the United States Patent and Trademark Office (USPTO) has granted powerful patent claims on the landmark patent application (WO2019183152) relating to the rational-based engineering of a key enzyme that is most efficient for large-scale microbial cannabinoid biosynthesis (i.e. NphB).
Biosynthesis is the production of molecules by living organisms. Engineers have learned to harness these powerful biological systems to produce specific materials for humanity’s benefit. By engineering the instructions for materials’ production into the genetic code of simple organisms—e.g. bacteria, algae, yeast and other fungi—they can acquire the novel ability to produce molecules they usually wouldn’t. A cornerstone technology of the bio revolution.
Renew Biopharma Inc is a research company developing proprietary therapeutics to treat neurodegenerative diseases, traumatic brain injuries (TBI), and for pain management. CEO Mike Mendez provides an introduction to the company and explains its interest in developing treatments using biosynthetic cannabinoids.
SAN FRANCISCO -- (BUSINESS WIRE) -- Michael Mendez, Renew Biopharma founder and CEO, and long-time biotech industry pioneer, will speak tomorrow about his company’s quest to look beyond the Cannabis plant to discover and develop “a new world of novel therapeutics” at SynBioBeta 2018.
NBC Bay Area 2 Part Series: Perhaps the biggest threat to contact sports, particularly football, is concussions. They’re ending careers early and leaving countless players with permanent brain damage. But new research in California suggests there could be a cure on the horizon.
San Diego — In 2014, Heron Therapeutics took notice of the role of postoperative pain in opioid addiction. So, the company dusted off a shelved drug program. Heron is among the San Diego pharma and biotechs rushing to market with alternatives to opioids, dependence on which mushroomed into a national health epidemic. Their treatments aim to prevent dependence, overdoses and side effects.
Renew Biopharma Launches Pre-Clinical Drug Discovery Program with Indiana University Bloomington’s Gill Center for Biomolecular Science Using Cannabinoids Grown in Microalgae
SAN DIEGO -- In a collaboration that could lead to a new class of drugs to replace opioids and help fight the national opioid epidemic, Renew Biopharma today announced it is collaborating with Ken Mackie from the Indiana University (Bloomington) Gill Center for Biomolecular Science to help screen and develop human therapeutics using Renew’s natural and novel cannabinoid molecules in a pre-clinical drug discovery program.